MarketPulse
N

$NGEN

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Nervgen Pharma Corp.

NervGen Pharma Raises $60M via Public Offering to Advance Spinal Cord Therapy

NervGen Pharma prices $60M public offering of 24M shares at $2.50 each to fund NVG-291 clinical development through 2026.
NGENwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Spinal Cord Injury Market Set to Quadruple as Six Therapies Challenge Treatment Void

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.
ABBVNGENclinical trialsmarket growth